The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study
Abstract
Selective serotonin reuptake inhibitors may be associated with new adverse events after abrupt discontinuation. Hypothesizing that the long half-life of fluoxetine would be protective, this study analyzed the effects of abrupt fluoxetine discontinuation during a randomized, double-blind, placebo-controlled study of depression maintenance treatment. After 12 weeks of fluoxetine treatment (20 mg/day), 395 responders were abruptly randomized to placebo (N = 96) or to continued fluoxetine (N = 299). Patients were seen at weeks 1, 2, 4, and 6 after randomization. Reports of new or worsened adverse events were similar for both groups at each visit after randomization. Patient discontinuations related to adverse events were also similar in both groups. Mild, self-limited lightheadedness or dizziness occurred in a small percentage of patients who discontinued fluoxetine treatment but was of little clinical significance. No cluster of symptoms suggestive of a discontinuation syndrome was observed. Abrupt discontinuation of fluoxetine treatment was well tolerated and did not seem to be associated with significant clinical risk. Fluoxetine may offer a potential safety advantage over shorter-acting agents with respect to treatment interruption and/or discontinuation and may be a better choice for those patients who are likely to miss doses because of travel or forgetfulness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Withdrawal symptoms are more common when SSRIs are given in higher doses 55,56 , or for longer periods 55 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [56]
Citations
Cites
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
Self-citationPhysical symptoms associated with paroxetine discontinuation
Barr, L. C., Goodman, W. K., & Price, L. H. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.2.289 · Cited by 71
Withdrawal phenomena associated with antidepressant and antipsychotic agents
Dilsaver, S. C. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00002 · Cited by 60
Extrapyramidal symptoms upon discontinuation of fluoxetine
Stoukides, J., & Stoukides, C. A. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.9.1263a · Cited by 56
Medication Withdrawal Symptoms in Obsessive-Compulsive Disorder Patients Treated with Paroxetine
Keuthen, N. J., Cyr, P., Ricciardi, J. A., Minichiello, W. E., Buttolph, M. L., & Jenike, M. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00010 · Cited by 53
Withdrawal reaction after sertraline discontinuation
Louie, A. K., Lannon, R. A., & Ajari, L. J. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.450b · Cited by 38
Physical symptoms associated with paroxetine withdrawal
DeBattista, C., & Schatzberg, A. F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1235b · Cited by 37
Research works printed but not linked: 5
- Debattista, 1995, Am J Psychiatry, 152, 1235
- Kouie, 1994, Am J Psychiatry, 151, 450
- Einbinder, 1995, Am J Psychiatry, 152, 1235
- Stoukides, 1991, Am J Psychiatry, 148, 1263
- Kasantikul, 1995, J Med Assoc Thai, 78, 53
Cited by
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Self-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Metadata
- Authors
- Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C.
- Affiliations
- Rush University Medical Center (US)
- Rush University (US)
- University of Pennsylvania (US)
- Columbia University (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1998-06
- Volume
- 18
- Issue
- 3
- Pages
- 193-197
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2015255754
- Semantic Scholar
- e4b1898cb3ec0a3c6ba46dfedb5191e8fdf6e17d
- Cited by
- 85
- References
- 8
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 8 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 2
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- fluoxetine, selective serotonin reuptake inhibitors, discontinuation syndrome, adverse events, drug safety, dizziness
- MeSH terms
- Adult, Depressive Disorder, Dizziness, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Prospective Studies, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/00004714-199806000-00003
- The paper
- Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C. (1998). Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199806000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.